Galapagos’ ziritaxestat hits primary endpoint in first systemic sclerosis study Sep. 11, 2020 By Michael Fitzhugh No Comments Results from the first trial testing the oral autotaxin inhibitor ziritaxestat in adults with diffuse cutaneous systemic sclerosis have encouraged its originator, Galapagos NV, to explore next steps for the program, it said on Sept. 11. Read More